Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland

The survey documents the effect of evidence and approval on clinical care with single agent prednisone representing the standard of care in 1<sup>st</sup>-line treatment while rux combined with steroids defines the new standard for 2<sup>nd</sup>-line treatment of cGVHD. ECP is used in case of contraindication for rux and both agents are also used in progressive onset cGVHD. In contrast, treatment of BOS and sclerotic cGVHD beyond 2<sup>nd</sup>-line treatment remains heterogeneous with new agents being integrated in the treatment landscape.

Authors

Institutions

Publication Details

Journal
Transplantation and Cellular Therapy
Published
2025-05-05
DOI
https://doi.org/10.1016/j.jtct.2025.04.017
Citations
2
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
3.54
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland

Guido Kobbe, Matthias Fante, Daniel Wolff, Julia Winkler et al.
2 citations
Transplantation and Cellular Therapy
Hematopoietic Stem Cell Transplantation
3.54
article

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland

Guido Kobbe, Matthias Fante, Daniel Wolff, Julia Winkler, Katharina Egger‐Heidrich, Inken Hilgendorf, Ánita Lawitschka, Silke Heidenreich, Olaf Penack, Julia Marx, Alexander Denk, William Krüger, Claudia Wehr, Jochen J. Frietsch, Gesine Bug, Irene Teichert von Lüttichau, Stefan Klein, Lutz Peter Mueller, Hildegard Greinix, Joerg Halter, Eva-Maria Wagner Drouet, Darina Kodzhabasheva
article en
2 citations

Abstract

The survey documents the effect of evidence and approval on clinical care with single agent prednisone representing the standard of care in 1<sup>st</sup>-line treatment while rux combined with steroids defines the new standard for 2<sup>nd</sup>-line treatment of cGVHD. ECP is used in case of contraindication for rux and both agents are also used in progressive onset cGVHD. In contrast, treatment of BOS and sclerotic cGVHD beyond 2<sup>nd</sup>-line treatment remains heterogeneous with new agents being integrated in the treatment landscape.

Transplantation and Cellular TherapyVol. 31(7)
Goethe University Frankfurt (DE), Universität Hamburg (DE), University of Freiburg (DE), Johannes Gutenberg University Mainz (DE), Medical University of Graz (AT), Heidelberg University (DE), Universitätsmedizin Greifswald (DE), University Hospital Heidelberg (DE), University Hospital of Basel (CH), University Hospital Regensburg (DE), Humboldt-Universität zu Berlin (DE), Universitätsklinikum Erlangen (DE), Düsseldorf University Hospital (DE), Klinik und Poliklinik für Kinder- und Jugendmedizin (DE), University Hospital Münster (DE), University Medical Center Hamburg-Eppendorf (DE), St Anna Children's Hospital (AT), Universitätsklinikum Würzburg (DE), University Hospital Frankfurt (DE), Jena University Hospital (DE), St.-Johannes-Hospital Dortmund (DE), University Hospital in Halle (DE), University Hospital Carl Gustav Carus (DE), Heinrich Heine University Düsseldorf (DE), Medical University of Vienna (AT)
Good health and well-being
Openalex Percentile: Top 8%
Hematopoietic Stem Cell Transplantation
3.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.